Epizyme, Inc. (EPZM)

[ottoman]

"Epizyme Major Shareholder Buys $7,999,920 in Stock (EPZM)"

http://www.wkrb13.com/markets/229356/epizyme-major-shareholder-buys-7999920-in-stock-epzm/

Epizyme (NASDAQ:EPZM) major shareholder M James Barrett purchased 406,500 shares of the company’s stock on the open market in a transaction that occurred on Friday, November 15th. The shares were purchased at an average cost of $19.68 per share, for a total transaction of $7,999,920.00. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Shares of Epizyme (NASDAQ:EPZM) opened at 19.00 on Monday. Epizyme has a one year low of $18.10 and a one year high of $45.72. The stock has a 50-day moving average of $36.20 and a 200-day moving average of $33.03. The company’s market cap is $539.8 million.

Separately, analysts at Citigroup Inc. reiterated a “buy” rating on shares of Epizyme in a research note to investors on Friday. They now have a $32.00 price target on the stock, down previously from $42.00. Five equities research analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and a consensus price target of $34.50.

Epizyme, Inc is a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize personalized therapeutics for patients with genetically defined cancers.